---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-006475"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2023-04-24T23:59:59+00:00"
generated_at: "2026-06-16T19:19:36.401689+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences appoints Jeffrey Dayno as permanent President & CEO; Aronin returns to non-executive Chairman

## Summary
- Dr. Jeffrey Dayno appointed President and CEO effective April 24, 2023; also joins Board as Class I director.
- Dayno previously served as Interim President and CEO since Jan 6, 2023, and CMO since 2017.
- Jeffrey Aronin returns from Executive Chairman to non-executive Chairman of the Board.
- Dayno's employment agreement: base salary $650,000, target bonus 75% of base (up to 100% under certain circumstances).
- Dayno stated WAKIX could be a $1B+ narcolepsy franchise with additional $1B potential from other indications.

## SEC filing metadata
- accession: 0001558370-23-006475
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2023-04-24T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837023006475/0001558370-23-006475-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837023006475/hrmy-20230424x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-006475
- JSON: https://secwatch.observer/filing/0001558370-23-006475.json
- Plain text: https://secwatch.observer/filing/0001558370-23-006475.txt

## Key facts
- Executive change
  Jeffrey M. Dayno was appointed as President and Chief Executive Officer at Harmony Biosciences Holdings, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: Dr. Jeffrey M. Dayno, the Company’s current Interim President and Chief Executive Officer and Chief Medical Officer, has been appointed by the Board of Directors of the Company (the “Board”) as President and Chief Executive Officer (“CEO”) of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837023006475/0001558370-23-006475-index.htm
- Executive change
  Jeffrey M. Dayno was appointed as Class I Director at Harmony Biosciences Holdings, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: Dr. Dayno has also been appointed to the Board as a Class I Director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837023006475/0001558370-23-006475-index.htm
- Executive change
  Jeffrey S. Aronin changed role as non-executive Chairman of the Board at Harmony Biosciences Holdings, Inc..
  - Action: returned to
  - Role: non-executive Chairman of the Board
  source text: Jeffrey S. Aronin, who has served at the Company’s Executive Chairman since January 2023, has returned to his prior role as non-executive Chairman of the Board, effective April 24, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837023006475/0001558370-23-006475-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.